Literature DB >> 25652040

The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells.

Y M AlSuleimani1,2, C R Hiley1.   

Abstract

BACKGROUND AND
PURPOSE: Lysophosphatidylinositol (LPI), a lipid signalling molecule, activates GPR55 and elevates intracellular Ca(2+). Here, we examine the actions of LPI in the rat resistance mesenteric artery and Ca(2+) responses in endothelial cells isolated from the artery. EXPERIMENTAL APPROACH: Vascular responses were studied using wire myographs. Single-cell fluorescence imaging was performed using a MetaFluor system. Hypotensive effects of LPI were assessed using a Biopac system. KEY
RESULTS: In isolated arteries, LPI-induced vasorelaxation was concentration- and endothelium-dependent and inhibited by CID 16020046, a GPR55 antagonist. The CB1 receptor antagonist AM 251 had no effect, whereas rimonabant and O-1918 significantly potentiated LPI responses. Vasorelaxation was reduced by charybdotoxin and iberiotoxin, alone or combined. LPI decreased systemic arterial pressure. GPR55 is expressed in rat mesenteric artery. LPI caused biphasic elevations of endothelial cell intracellular Ca(2+). Pretreatment with thapsigargin or 2-aminoethoxydiphenyl borate abolished both phases. The PLC inhibitor U73122 attenuated the initial phase and enhanced the second phase, whereas the Rho-associated kinase inhibitor Y-27632 abolished the late phase but not the early phase. CONCLUSIONS AND IMPLICATIONS: LPI is an endothelium-dependent vasodilator in the rat small mesenteric artery and a hypotensive agent. The vascular response involves activation of Ca(2+)-sensitive K(+) channels and is not mediated by CB1 receptors, but unexpectedly enhanced by antagonists of the 'endothelial anandamide' receptor. In endothelial cells, LPI utilizes PLC-IP3 and perhaps ROCK-RhoA pathways to elevate intracellular Ca(2+). Overall, these findings support an endothelial site of action for LPI and suggest a possible role for GPR55 in vasculature.
© 2015 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25652040      PMCID: PMC4459022          DOI: 10.1111/bph.13107

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  64 in total

1.  Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by Galpha13.

Authors:  M J Hart; X Jiang; T Kozasa; W Roscoe; W D Singer; A G Gilman; P C Sternweis; G Bollag
Journal:  Science       Date:  1998-06-26       Impact factor: 47.728

Review 2.  Endothelial atypical cannabinoid receptor: do we have enough evidence?

Authors:  Alexander I Bondarenko
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

3.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  Expression and function of endothelial Ca(2+)-activated K(+) channels in human mesenteric artery: A single-cell reverse transcriptase-polymerase chain reaction and electrophysiological study in situ.

Authors:  R Köhler; C Degenhardt; M Kühn; N Runkel; M Paul; J Hoyer
Journal:  Circ Res       Date:  2000-09-15       Impact factor: 17.367

5.  Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor.

Authors:  László Offertáler; Fong-Ming Mo; Sándor Bátkai; Jie Liu; Malcolm Begg; Raj K Razdan; Billy R Martin; Richard D Bukoski; George Kunos
Journal:  Mol Pharmacol       Date:  2003-03       Impact factor: 4.436

6.  Release of the mitogen lysophosphatidylinositol from H-Ras-transformed fibroblasts; a possible mechanism of autocrine control of cell proliferation.

Authors:  M Falasca; C Iurisci; A Carvelli; A Sacchetti; D Corda
Journal:  Oncogene       Date:  1998-05-07       Impact factor: 9.867

7.  p160ROCK mediates RhoA activation of Na-H exchange.

Authors:  T Tominaga; T Ishizaki; S Narumiya; D L Barber
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

8.  Mechanisms of vasorelaxation induced by oleoylethanolamide in the rat small mesenteric artery.

Authors:  Yousuf M AlSuleimani; C Robin Hiley
Journal:  Eur J Pharmacol       Date:  2013-01-20       Impact factor: 4.432

9.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

10.  Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant.

Authors:  H Wulff; M J Miller; W Hansel; S Grissmer; M D Cahalan; K G Chandy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

View more
  12 in total

1.  Lysophosphatidylinositol-induced activation of the cation channel TRPV2 triggers glucagon-like peptide-1 secretion in enteroendocrine L cells.

Authors:  Kazuki Harada; Tetsuya Kitaguchi; Taichi Kamiya; Kyaw Htet Aung; Kazuaki Nakamura; Kunihiro Ohta; Takashi Tsuboi
Journal:  J Biol Chem       Date:  2017-05-22       Impact factor: 5.157

Review 2.  The endocannabinoid system in cardiovascular function: novel insights and clinical implications.

Authors:  Salvador Sierra; Natasha Luquin; Judith Navarro-Otano
Journal:  Clin Auton Res       Date:  2017-12-08       Impact factor: 4.435

3.  Preclinical safety and efficacy of cannabidivarin for early life seizures.

Authors:  Megan N Huizenga; Alberto Sepulveda-Rodriguez; Patrick A Forcelli
Journal:  Neuropharmacology       Date:  2019-01-10       Impact factor: 5.250

4.  GPR55-mediated effects on brain microvascular endothelial cells and the blood-brain barrier.

Authors:  Luciana M Leo; Boluwatife Familusi; Michelle Hoang; Raymond Smith; Kristen Lindenau; Kevin T Sporici; Eugen Brailoiu; Mary E Abood; G Cristina Brailoiu
Journal:  Neuroscience       Date:  2019-07-04       Impact factor: 3.590

5.  GPR55 agonist lysophosphatidylinositol and lysophosphatidylcholine inhibit endothelial cell hyperpolarization via GPR-independent suppression of Na+-Ca2+ exchanger and endoplasmic reticulum Ca2+ refilling.

Authors:  Alexander I Bondarenko; Fabrizio Montecucco; Olga Panasiuk; Vadim Sagach; Nataliya Sidoryak; Karim J Brandt; François Mach
Journal:  Vascul Pharmacol       Date:  2017-01-05       Impact factor: 5.773

6.  A role for GPR55 in human placental venous endothelial cells.

Authors:  Julia Kremshofer; Monika Siwetz; Veronika M Berghold; Ingrid Lang; Berthold Huppertz; Martin Gauster
Journal:  Histochem Cell Biol       Date:  2015-04-14       Impact factor: 4.304

Review 7.  Lysophosphatidylinositol Signalling and Metabolic Diseases.

Authors:  Syamsul A Arifin; Marco Falasca
Journal:  Metabolites       Date:  2016-01-15

Review 8.  An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors.

Authors:  Paula Morales; Patricia H Reggio
Journal:  Cannabis Cannabinoid Res       Date:  2017-10-01

9.  l-α-Lysophosphatidylinositol (LPI) aggravates myocardial ischemia/reperfusion injury via a GPR55/ROCK-dependent pathway.

Authors:  Olivia J Robertson-Gray; Sarah K Walsh; Erik Ryberg; Ann-Cathrine Jönsson-Rylander; Christopher Lipina; Cherry L Wainwright
Journal:  Pharmacol Res Perspect       Date:  2019-05-24

10.  A Novel Alternative in the Treatment of Detrusor Overactivity? In Vivo Activity of O-1602, the Newly Synthesized Agonist of GPR55 and GPR18 Cannabinoid Receptors.

Authors:  Andrzej Wróbel; Aleksandra Szopa; Anna Serefko; Ewa Poleszak
Journal:  Molecules       Date:  2020-03-18       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.